<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
Sign Up
    February 28, 2017

    Make Better Drug Discovery Decisions through Collaborative Analytics

    Join Dr. Chris Cooper (TB Alliance) and Dr. Matt Segall (Optibrium) as they discuss different approaches they are applying to achieve better outcomes in neglected disease research. They will share their successes in fostering better collaborative dynamics, and discuss the use of technologies aiding visualization and data analytics.

    Drug Discovery Informatics Neglected Disease Research Webinar

    There are critical human health issues that are not well addressed by academic or industrial researchers in today’s natural drug discovery marketplace. Areas like rare and neglected diseases, as well as antimicrobial resistance, simply are not spontaneously “solved” with our current system. Significant scientific, social, and technological changes could improve the landscape if we were to “Think Different”, according to the succinct motto by Steve Jobs that has permeated the collective consciousness outside of  Silicon Valley.

    Specifically for treating Tuberculosis (TB), the challenges are significant. The standardized Directly Observed Therapy “Short-course” (DOTS), a complex combination of pills taken daily for 6-9 months, provides the first challenge. The emergence of MDR-TB, XDR-TB, and TDR-TB is another hurdle. And complications related to immune suppression for individuals with HIV and TB co-infection provides a third challenge. Intellectually, there is also the scientific challenge of growing our basic understanding of the biology of latent versus active TB, and TB’s response to the range of potential treatments.

    New approaches, new collaborations, and new technologies must be utilized to help in this challenging arena. We are pleased to have leading experts in the field share the latest approaches to collaboration against neglected diseases: Dr. Christopher Cooper of TB Alliance, and Dr. Matt Segall of Optibrium.

    Optibrium Stardrop technologies, like the CDD Vault platform, are “therapeutic area agnostic” tools.  Thus the stories shared and lessons learned for TB will resonate across many therapeutic areas and with many drug discovery hunters.

    Register Now!


    • Wednesday, March 29th, 2017
    • 9:00 (US Pacific), 12:00 (US Eastern), 17:00 (GMT)


    Chris Cooper TB Alliance   Matt Segall Optibrium

    • Chris Cooper, Senior Directory of Chemistry, TB Alliance, New York, NY
    • Matt Segall, CEO and Company Director, Optibrium Ltd, Cambridge UK

    Join our distinguished panel of speakers as they deviate from the expected “PowerPoint presentation” style webinar to provide an engaging Town Hall experience.

    Register Now to reserve your attendee slot!

    Big thanks to our sponsors for allowing us to freely share these timely updates!

    • Lab Launch
    • MolPort
    • wega_logo_300


    also thanks to the Research Data Alliance.

    This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities.

    CDD Vault: Drug Discovery Informatics your whole project team will embrace

    Other posts you might be interested in

    View All Posts
    CDD Blog
    8 min   July 22, 2024
    Drug Discovery Industry Roundup with Barry Bunin — July, 22 2024
    Read More
    CDD Blog
    34 min   July 1, 2024
    Critical Data Considerations for All Lifecycle Stages of a Biotech Startup
    Read More
    CDD Vault Snack
    3 min   June 27, 2024
    Vault Snack #24 - New Interface, Features & Infrastructure for the CDD Vault ELN
    Read More